Table 3. Treatment outcome and sputum smear result of tuberculosis patients.
| Characteristics | Tuberculosis treatment | ||||||
|---|---|---|---|---|---|---|---|
| RHZ | RHEZ-FDC | ||||||
| ADR n = 55 |
No ADR n = 310 |
p-value | ADR n = 86 |
No ADR n = 279 |
p-value | p-value* | |
| Age in years** | 35 ± 11 | 37 ± 13 | 0.32 | 41 ± 12 | 39 ± 13 | 0.02 | 0.08 |
| Range age ≥30 years | 36 (65.5) | 191 (61.6) | 0.65 | 64 (74.4) | 197 (70.6) | 0.005 | 0.01 |
| Female | 32 (58.2) | 125 (40.3) | 47 (54.7) | 118 (42.3) | |||
| Pulmonary TB presentation | 50 (90.9) | 286 (92.3) | 0.02 | 76 (88.4) | 248 (88.9) | 0.048 | 0.002 |
| Treatment outcome | 0.42 | 0.55 | 0.41 | ||||
| Cure1 | 47 (85.5) | 266 (85.8) | 75 (87.2) | 251 (90) | |||
| Failure2 | 0 (0) | 3 (1) | 0 (0) | 0 (0) | |||
| Not evaluated3 | 1 (1.7) | 0 (0) | 3(3.5) | 0 (0) | |||
| Death4 | 3 (5.5) | 6 (1.9) | 2 (2.3) | 5 (1.8) | |||
| Lost to follow-up5 | 4 (7.3) | 20 (6.5) | 6 (7) | 10 (3.6) | |||
| MDR6 | 1 (1.8) | 15 (4.8) | 0.48 | 3 (3.5) | 13 (4.7) | 0.78 | 0.49 |
| Diabetes | 4 (7.3) | 25 (8.1) | 1.00 | 14 (16.3) | 19 (6.8) | 0.16 | 0.06 |
| Hypertension | 1 (1.8) | 1 (0.3) | 0.28 | 2 (2.3) | 3 (1.1) | 0.34 | 0.14 |
| Past or current alcohol consumption | 18 (33.8) | 32 (2.3) | <0.01 | 15 (17.4) | 52 (18.6) | 0.78 | 0.08 |
| Past or current cigarette smoking | 19 (34.5) | 58 (18.7) | 0.02 | 25 (29.1) | 74 (26.5) | 0.78 | 0.09 |
| Illicit drug use | 1 (1.8) | 5 (1.6) | 1.00 | 3 (3.5) | 4 (1.4) | 0.38 | 0.29 |
| Concomitant medication | 3 (5.5) | 2 (0.6) | 0.03 | 3 (3.5) | 6 (2.2) | 0.46 | 0.04 |
Data represent no. (%), except age, represented in mean and standard deviation (SD)
* Mantel-Haenszel Test (MH) for comparison of patients with ADRs between treatment groups
** ANOVA for com for comparison of patients with ADRs between treatment groups
1Cured: A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who was smear- or culture-negative in the last month of treatment and on at least one previous occasion.
2Failure: Persistence of positive sputum at the end of treatment also classified as failure cases that at the beginning of treatment, are strongly positive (++ or +++) and maintain this situation until the fourth month, or those with initial positivity followed by negativity, and new positivity for two consecutive months, from the fourth month treatment.
3Not evaluated: A TB patient for whom no treatment outcome is assigned. This includes cases “transferred out” to another treatment unit.
4Death: A TB patient who dies for any reason before starting or during the course of treatment
5Lost to follow-up: A TB patient who did not start treatment or whose treatment was interrupted for two consecutive months or more
6MDR: Multidrug-resistant tuberculosis